Details of the Drug

General Information of Drug (ID: DMWD8WG)

Drug Name

JNJ-64251330

Synonyms

Lorpucitinib; Lorpucitinib [INN]; OE1QTY7C25; UNII-OE1QTY7C25; 2230282-02-5; 1-(trans-4-(Cyanomethyl)cyclohexyl)-1,6-dihydro-N-(2-hydroxy-2-methylpropyl)imidazo(4,5-d)pyrrolo(2,3-b)pyridine-2-acetamide; Imidazo(4,5-d)pyrrolo(2,3-b)pyridine-2-acetamide, 1-(trans-4-(cyanomethyl)cyclohexyl)-1,6-dihydro-N-(2-hydroxy-2-methylpropyl)-; CHEMBL4473572; SCHEMBL20266878; SCHEMBL20266879; GTPL10631; BDBM387818; BDBM505107; US10294226, Compound Ex. 1; compound 2 [PMID: 32134643]; example 1 [WO2018112379A1]; JNJ64251330; JNJ-64251330; MS-27023; US11066406, Ex. 1; HY-109182; CS-0116453; 2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)-N-(2-hydroxy-2-methylpropyl)acetamide; 2-[3-[4-(cyanomethyl)cyclohexyl]-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaen-4-yl]-N-(2-hydroxy-2-methylpropyl)acetamide; 2-{1-[trans-4-(cyanomethyl)cyclohexyl]-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl}-N-(2-hydroxy-2-methylpropyl)acetamide

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C22H28N6O2
Canonical SMILES: CC(C)(CNC(=O)CC1=NC2=CN=C3C(=C2N1C4CCC(CC4)CC#N)C=CN3)O
InChI: InChI=1S/C22H28N6O2/c1-22(2,30)13-26-19(29)11-18-27-17-12-25-21-16(8-10-24-21)20(17)28(18)15-5-3-14(4-6-15)7-9-23/h8,10,12,14-15,30H,3-7,11,13H2,1-2H3,(H,24,25)(H,26,29)
InChIKey: NJKMSBSVJSQUBU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 134611548
TTD ID: DSUT71

References

1	ClinicalTrials.gov (NCT05014360) A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis. U.S.National Institutes of Health.